Subcutaneous Immunoglobulin (SCIG) Market Growth Is Reshaping Competitive Advantage Across The Industry
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Subcutaneous Immunoglobulin (SCIG) Market Value Analysis: What Growth Is Expected Over The Forecast Period?
The market for subcutaneous immunoglobulin (SCIG) has experienced substantial expansion in recent years. Its value is projected to rise from $14.39 billion in 2025 to $16.32 billion in 2026, reflecting a compound annual growth rate (CAGR) of 13.4%. Historical growth has been driven by a higher diagnosis rate of primary immunodeficiency disorders, the drawbacks associated with intravenous immunoglobulin therapy, a growing demand for sustained immune assistance, an enhanced safety record for SCIG, and an increasing patient inclination toward receiving care at home.
Over the coming years, the subcutaneous immunoglobulin (SCIG) market is poised for substantial expansion, with projections indicating a climb to $25.71 billion by 2030, driven by a compound annual growth rate (CAGR) of 12.0%. This forecasted growth is fueled by factors such as the broadening of SCIG applications beyond immunodeficiency conditions, a heightened emphasis on homecare therapies within the healthcare sector, advancements in infusion device technology, a rising incidence of autoimmune and neurological disorders, and an increasing preference for patient-focused treatment approaches. Key developments shaping the market include a notable transition from intravenous immunoglobulin (IVIG) to SCIG treatments, growing adoption of immunoglobulin therapy administered at home, a heightened inclination toward self-administration devices, the expanding use of SCIG in managing chronic immune disorders, and an elevated demand for long-term immune replacement solutions.
Download A Free Sample Report For Comprehensive Market Insights:
Subcutaneous Immunoglobulin (SCIG) Market Growth Factors Supporting Long-Term Expansion
The rising occurrence of secondary immunodeficiency conditions is anticipated to boost expansion within the subcutaneous immunoglobulin market. Such conditions involve a weakened or compromised immune system stemming from causes external to the immune system itself. Contributing factors to their increased prevalence include aging demographics, the administration of immunosuppressive therapies, and exposure to environmental pollutants. Subcutaneous immunoglobulin treatment supplies antibodies that reinforce a compromised immune response, proving particularly useful in managing chronic illnesses like HIV or autoimmune diseases, thereby reducing infection risk and supporting immune function throughout therapy. For example, data from October 2024 from HIV i-Base, a UK-based activist organization focused on treatment, revealed that in 2023 there was a 36% uptick in new HIV diagnoses among heterosexual men—rising from 445 in 2022 to 605—and a 30% increase among heterosexual women, climbing from 602 in 2022 to 780. Consequently, this growing frequency of secondary immunodeficiency diseases is accelerating the subcutaneous immunoglobulin market’s development.
An escalating prevalence of neurological disorders is predicted to fuel the forward momentum of the subcutaneous immunoglobulin market. These conditions encompass abnormalities of the nervous system affecting the brain, spinal cord, or peripheral nerves—examples include acute spinal cord injuries, Alzheimer’s dementia, ALS, ataxia, and brain tumors—and involve structural, biochemical, or electrical irregularities. Their increasing occurrence stems from influences such as an aging population, environmental contaminants, hereditary factors, and shifts in lifestyle habits. Subcutaneous immunoglobulin therapy aids in managing these disorders by delivering antibodies that modulate immune activity, reduce inflammatory processes, and stabilize neuromuscular junctions, potentially decelerating disease advancement while alleviating symptoms. As an illustration, in March 2023 the Alzheimer’s Association, a non-profit voluntary health organization based in the US, reported that 6.7 million Americans aged 65 years or older are currently affected by Alzheimer’s dementia, with forecasts indicating this number could reach 13.8 million by 2060. Hence, the expanding number of neurological conditions is a key driver propelling the subcutaneous immunoglobulin market.
Subcutaneous Immunoglobulin (SCIG) Market Segment Landscape And Growth Potential
The subcutaneous immunoglobulin (scig) market covered in this report is segmented –
1) By Product Type: Immunoglobulin A (IgA), Immunoglobulin G (IgG)
2) By Application: Primary Immunodeficiency Disorders, Autoimmune Diseases, Neurological Disorders, Other Applications
3) By End-Use: Clinics, Hospitals, Homecare, Other End-Uses
Subsegments:
1) By Immunoglobulin A (IgA): IgA1, IgA2
2) By Immunoglobulin G (IgG): IgG1, IgG2, IgG3, IgG4
Subcutaneous Immunoglobulin (SCIG) Market Industry Trends Shaping Future Revenue Growth
Key industry players in the subcutaneous immunoglobulin (SCIG) sector are directing their efforts toward the creation of innovative products, specifically prefilled and ready-to-use formulations, aimed at streamlining treatment, enabling at-home self-administration, and elevating the patient experience overall. These ready-to-use SCIG preparations are standardized, premeasured immunoglobulin solutions intended for delivery beneath the skin, offering individuals suffering from primary immunodeficiency and related immunological conditions a simpler way to manage their therapy away from hospitals or clinics. As an example, in April 2023, Hizentra’s new 50 mL / 10 g prefilled syringe received approval from the U.S. Food and Drug Administration (FDA). This patient-friendly, ready-to-administer option facilitates easier home-based infusions and contributes to better adherence to prescribed treatment regimens.
Subcutaneous Immunoglobulin (SCIG) Market Competitive Landscape: Who Are The Leading Companies?
Major companies operating in the subcutaneous immunoglobulin (scig) market are CSL Behring, Grifols S.A., Octapharma AG, Kedrion Biopharma, LFB Group, Biotest AG, Bio Products Laboratory Ltd., ADMA Biologics Inc., Kamada Pharmaceuticals, Takeda Pharmaceutical Company Limited, Baxter International Inc., Bharat Serums and Vaccines Limited, Emergent BioSolutions Inc., Pfizer Inc., Johnson & Johnson, Lonza Group, Argenx SE, CinnaGen Co., Intas Pharmaceuticals Ltd., Dr. Reddy’s Laboratories Ltd.
Access The Complete Subcutaneous Immunoglobulin (SCIG) Market Report:
Subcutaneous Immunoglobulin (SCIG) Market Regional Distribution: Which Areas Drive Market Expansion?
North America was the largest region in the subcutaneous immunoglobulin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the subcutaneous immunoglobulin (scig) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
